|
|
|
|
|
|
|
EXPERT-LED JOURNAL CLUB DISCUSSIONS |
|
|
|
|
|
| 225Actinium PSMA-617 and 177Lutetium PSMA-617 Tandem Therapy in mCRPC Patients, Journal Club
|
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen discuss a publication about 225Actinium PSMA-617 and 177Lutetium PSMA-617 tandem therapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have previously been treated with 177Lutetium PSMA-617 monotherapy.
|
|
|
|
|
|
|
|
|
| The Use of MRI With Targeted Biopsy in Prostate Cancer Screening - Journal Club
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Zachary Klaassen and Christopher Wallis discuss the abstract "MRI-Targeted or Standard Biopsy in Prostate Cancer Screening," in this UroToday Journal Club. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential to address the challenge of overdiagnosis in prostate cancer screening.
|
|
|
|
|
|
|
|
|
|
|
| The First Multiplex Gene Expression Liquid Biopsy Assay to Assess Potential ARSI Resistant Mechanisms Simultaneously In the Treatment of Metastatic Prostate Cancer - Journal Club
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss a Journal of Clinical Oncology publication entitled, "Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer."
|
|
|
|
|
|
| OLIGOPELVIS GETUG P07, Salvage Radiotherapy Combined With Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer, Journal Club |
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen review the published OLIGOPELVIS GETUG P07 trial, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer. |
|
|
|
|
|
 |
|
|
|
|
|
